Abstract

The purpose of this study was to determine the phenotyping of Peripheral Blood Lymphocytes (PBL) in Head and Neck Cancers (HNCA) patients and to relate this with the level of Cell-Mediated Immunity (CMI) measured by in vitro lymphoproliferative assay, in order to evaluate immune suppression in HNCA patients and its possible mechanisms. Accordingly, one hundred twenty two HNCA patients and 100 control subjects were enrolled in this study. HNCA patients were classified into 42 nasopharyngeal carcinoma, 66 carcinoma of larynx and 14 Hypo Pharyngeal Carcinoma (HPC). For measuring CMI, Microculture Tetrazolium assay (MTT) was applied on the freshly isolated lymphocytes of HNCA patients and control group. Immunophenotyping of PBL was carried out for monitoring the blood level of CD3+, CD4+, CD8+, CD21+ cells in HNCA patients in comparison with controls. The results of both assays have been integrated, revealed the presence of remarked immune suppression in HNCA patients in comparison with the controls, especially for NasoPharyngeal Carcinoma (NPC) patients who were immunosuppressed more than other studied HNCA types. Surprisingly, NPC group showed the lowest CMI level along with the highest level of PBL subsets, particularly NPC patients expressed the highest level of CD8+ cells among HNCA. It was inferred that CD8+ cells were more likely immune suppressor rather than cytotoxic cells and this is the principal factor for inducing sustained immunosuppression in HNCA and in NPC in particular. Furthermore CD4/CD8 ratio proved to be a reliable index for assessing the immunological status of HNCA patients and more dependable index than other immunity-evaluating factors.

Highlights

  • Cancers in general are susceptible to immunemediated destruction and has been shown that many cancer patients have defects in their cellular immunological function, this is especially characteristic of those with Head and Neck Cancers (HNCA) that is strictly related to viral origin, Epstein Barr Virus (EBV)[1]

  • Immune suppression featured by Microculture Tetrazolium assay (MTT) assay: The first step for evaluating the immune status of HNCA patients was by evaluating the Cell-Mediated Immunity (CMI) level in HNCA patients in comparison with that of the control group by exploiting the potential of Peripheral Blood Lymphocytes (PBL) to be stimulated by different mitogenic substances

  • It was found that NasoPharyngeal Carcinoma (NPC) patients had significantly the lowest proliferative percentage among all HNCA patients which was 42.5%, while in laryngeal carcinoma patients the proliferative percentage was 78.7% and the highest level was in hypopharyngeal carcinoma which was 107.7%

Read more

Summary

Introduction

Cancers in general are susceptible to immunemediated destruction and has been shown that many cancer patients have defects in their cellular immunological function, this is especially characteristic of those with HNCA that is strictly related to viral origin, Epstein Barr Virus (EBV)[1]. Peripheral Blood Lymphocytes (PBL) can give a reliable monitoring of the immunological status in patients with cancers[6]. PBL CD markering is one of the main approaches that has been used to clarify the lines of immune defense mechanisms that exert an active role in the defense against tumor cells of HNCA[7]. It has been established that CD8+ cells are of a role in inducing immune suppression state in HNCA patients[8,9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call